Young Hak Kim

9.4k total citations
127 papers, 2.8k citations indexed

About

Young Hak Kim is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Young Hak Kim has authored 127 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Oncology, 80 papers in Pulmonary and Respiratory Medicine and 24 papers in Molecular Biology. Recurrent topics in Young Hak Kim's work include Lung Cancer Treatments and Mutations (66 papers), Lung Cancer Research Studies (49 papers) and Lung Cancer Diagnosis and Treatment (29 papers). Young Hak Kim is often cited by papers focused on Lung Cancer Treatments and Mutations (66 papers), Lung Cancer Research Studies (49 papers) and Lung Cancer Diagnosis and Treatment (29 papers). Young Hak Kim collaborates with scholars based in Japan, South Korea and United States. Young Hak Kim's co-authors include Michiaki Mishima, Yuichi Sakamori, Tadashi Mio, Yosuke Togashi, Katsuhiro Masago, Hiroki Nagai, Toyohiro Hirai, Hironori Yoshida, Masahide Fukudo and Yasuaki Ikemi and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Young Hak Kim

122 papers receiving 2.8k citations

Peers

Countries citing papers authored by Young Hak Kim

Since Specialization

Citations

This map shows the geographic impact of Young Hak Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Young Hak Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Young Hak Kim more than expected).

Fields of papers citing papers by Young Hak Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Young Hak Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Young Hak Kim. The network helps show where Young Hak Kim may publish in the future.

Co-authorship network of co-authors of Young Hak Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Young Hak Kim. A scholar is included among the top collaborators of Young Hak Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Young Hak Kim. Young Hak Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A randomized phase III study of docetaxel alone versus docetaxel plus S‐1 in patients with previously treated non‐small cell lung cancer: JMTO LC09‐01 2023 ·Thoracic Cancer ·Shinji Atagi, Takashi Daimon, Kyoichi Okishio, Kiyoshi Komuta, Yoshio Okano, Koichi Minato, Young Hak Kim, (unknown), Chiharu Tabata, Atsuhisa Tamura, Masaaki Kawahara	1
2	TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study 2023 ·JTO Clinical and Research Reports ·Yuki Katayama, Tadaaki Yamada, Kenji Morimoto, Hiroyuki Fujii, (unknown), Keiko Tanimura, Takayuki Takeda, (unknown), Shinsuke Shiotsu, Yusuke Chihara, Osamu Hiranuma, Takahiro Yamada, (unknown), Taishi Harada, Isao Hasegawa, Akihiro Yoshimura, Masahiro Iwasaku, Shinsaku Tokuda, Young Hak Kim, Koichi Takayama	5
3	Early Tumor Shrinkage as a Predictor of Favorable Treatment Outcomes in Patients With Extensive-Stage SCLC Who Received Programmed Cell Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy: A Prospective Observational Study 2023 ·JTO Clinical and Research Reports ·(unknown), Kenji Morimoto, Tadaaki Yamada, Takayuki Takeda, Shinsuke Shiotsu, (unknown), Taishi Harada, Nobuyo Tamiya, Yusuke Chihara, (unknown), Takahiro Yamada, (unknown), Masahiro Iwasaku, Shinsaku Tokuda, Young Hak Kim, Koichi Takayama	3
4	Incidence and Risk Factors of Symptomatic Radiation Pneumonitis in Non–Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy and Consolidation Durvalumab 2021 ·Clinical Lung Cancer ·Takashi Shintani, (unknown), Yukinori Matsuo, Masakazu Ogura, Takamasa Mitsuyoshi, Norio Araki, Kota Fujii, (unknown), Kiyoshi Nakamatsu, Takahiro Kishi, (unknown), Takashi Sakamoto, Masaru Narabayashi, (unknown), Masato Sakamoto, (unknown), (unknown), Young Hak Kim, Takashi Mizowaki	34
5	Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer 2021 ·Scientific Reports ·(unknown), Hiroaki Ozasa, Susumu Satô, Tomoko Funazo, Yuichi Sakamori, Takashi Nomizo, (unknown), (unknown), Kazutaka Hosoya, (unknown), Takahiro Tsuji, Hironori Yoshida, Ryo Itotani, (unknown), Young Hak Kim, Shigeo Muro, Toyohiro Hirai	14
6	Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model 2020 ·Molecular Cancer Therapeutics ·Tomoko Funazo, Takahiro Tsuji, Hiroaki Ozasa, Koh Furugaki, Yasushi Yoshimura, Tetsuya Oguri, (unknown), Yuto Yasuda, Takashi Nomizo, Yuichi Sakamori, Hironori Yoshida, Young Hak Kim, Toyohiro Hirai	5
7	Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab 2019 ·PLoS ONE ·Ichiro Yamauchi, Akihiro Yasoda, Shigemi Matsumoto, Yuichi Sakamori, Young Hak Kim, Motoo Nomura, Atsushi Otsuka, Toshinari Yamasaki, Ryoichi Saito, Morimasa Kitamura, Toshio Heike, Masakatsu Hishizawa, Nobuko Kawaguchi‐Sakita, Toshihito Fujii, Daisuke Taura, Masakatsu Sone, Nobuya Inagaki	105
8	Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model 2018 ·Molecular Cancer Research ·Takahiro Tsuji, Hiroaki Ozasa, Wataru Aoki, Shunsuke Aburaya, Tomoko Funazo, Koh Furugaki, Yasushi Yoshimura, (unknown), (unknown), Yuto Yasuda, Takashi Nomizo, Kiyoshi Uemasu, Koichi Hasegawa, Hironori Yoshida, (unknown), Hiroki Nagai, Yuichi Sakamori, Mitsuyoshi Ueda, Toyohiro Hirai, Young Hak Kim	41
9	Phase II study of ceritinib in alectinib‐pretreated patients with anaplastic lymphoma kinase‐rearranged metastatic non‐small‐cell lung cancer in Japan: ASCEND‐9 2018 ·Cancer Science ·Toyoaki Hida, Takashi Seto, Hidehito Horinouchi, Makoto Maemondo, Masayuki Takeda, Katsuyuki Hotta, Fumihiko Hirai, Young Hak Kim, Shingo Matsumoto, Masayuki Itô, Koichi Ayukawa, (unknown), (unknown), (unknown), Makoto Nishio	43
10	Nasogastric tube‐administered alectinib achieved long‐term survival in a crizotinib‐refractory nonsmall cell lung cancer patient with a poor performance status 2017 ·Clinical Case Reports ·Osamu Kanai, Young Hak Kim, Koichi Nakatani, Kohei Fujita, Tadashi Mio	4
11	Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer 2016 ·Molecular Cancer Therapeutics ·Yoshihisa Kobayashi, Koichi Azuma, Hiroki Nagai, Young Hak Kim, Yosuke Togashi, (unknown), Masato Chiba, Masaki Shimoji, Katsuaki Sato, Kenji Tomizawa, Toshiki Takemoto, Kazuto Nishio, Tetsuya Mitsudomi	57
12	Albumin-bound paclitaxel for the treatment of refractory or relapsed small-cell lung cancer 2016 ·Molecular and Clinical Oncology ·Hironori Yoshida, Young Hak Kim, Hiroaki Ozasa, Hiroki Nagai, Yuichi Sakamori, Takashi Nakaoku, (unknown), Takahiro Tsuji, Takashi Nomizo, Michiaki Mishima	10
13	Predictors of Permanent Pacemaker Insertion Following Transcatheter Aortic Valve Replacement With the CoreValve Revalving System Based on Computed Tomography Analysis: An Asian Multicenter Registry Study. 2015 ·PubMed ·(unknown), Young‐Guk Ko, Seungbong Han, Young Hak Kim, (unknown), (unknown), Michael Lee, Hyo-Soo Kim, Myeong‐Ki Hong, Yangsoo Jang, Eberhard Grube, Seung‐Jung Park	12
14	Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients 2015 ·Cancer Chemotherapy and Pharmacology ·Haruka Shinke, Satohiro Masuda, (unknown), Yasuaki Ikemi, (unknown), Tomoko Sato, Young Hak Kim, Michiaki Mishima, Takaharu Ichimura, Joseph V. Bonventre, Kazuo Matsubara	72
15	High-Dose Crizotinib for Brain Metastases Refractory to Standard-Dose Crizotinib 2013 ·Journal of Thoracic Oncology ·Young Hak Kim, Hiroaki Ozasa, Hiroki Nagai, Yuichi Sakamori, Hironori Yoshida, (unknown), Takashi Nakaoku, Michiaki Mishima	35
16	Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma 2010 ·Cancer ·Yosuke Togashi, Katsuhiro Masago, Takeshi Kubo, Yuichi Sakamori, Young Hak Kim, Yukimasa Hatachi, Akiko Fukuhara, Tadashi Mio, Kaori Togashi, Michiaki Mishima	55
17	Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420 in Patients with Non-small Cell Lung Cancer and Chronic Renal Failure Who Are Undergoing Hemodialysis 2010 ·Journal of Thoracic Oncology ·Yosuke Togashi, Katsuhiro Masago, Masahide Fukudo, Tomohiro Terada, Yasuaki Ikemi, Young Hak Kim, Shiro Fujita, Kaoru Irisa, Yuichi Sakamori, Tadashi Mio, Ken‐ichi Inui, Michiaki Mishima	42
18	Pulmonary embolism due to internal jugular vein thrombosis in a patient with non-small cell lung cancer receiving bevacizumab 2010 ·International Journal of Clinical Oncology ·Yosuke Togashi, Young Hak Kim, Katsuhiro Masago, (unknown), Yuichi Sakamori, Tadashi Mio, Michiaki Mishima	6
19	Successful treatment with carboplatin and etoposide in a small-cell lung cancer patient undergoing hemodialysis 2009 ·Respiratory Medicine CME ·Young Hak Kim, Tadashi Mio, (unknown), Michiaki Mishima	1
20	Clinical Analysis of Spontaneous Pneumomediastinum 2006 ·The Korean Journal of Thoracic and Cardiovascular Surgery ·(unknown), (unknown), (unknown), (unknown), Young Hak Kim	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact